Home/Pipeline/Imfinzi (durvalumab)

Imfinzi (durvalumab)

Various cancers

ApprovedCommercial

Key Facts

Indication

Various cancers

Phase

Approved

Status

Commercial

Company

AstraZeneca

About AstraZeneca

AstraZeneca is one of the world's largest pharmaceutical companies, headquartered in Cambridge, UK, with a market capitalization of approximately $285 billion. The company focuses on transformative science including next-generation therapeutics, AI-driven drug discovery, and personalized medicine approaches. AstraZeneca reported strong commercial performance in 2025 with 16 positive Phase 3 study results announced during the year, demonstrating continued pipeline strength across multiple therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Respiratory Metabolic Diseases Immunology Rare Diseases

Other Various cancers Drugs

Drug	Company	Phase	Status
Retifanlimab	Eli Lilly	Phase 2/3	Active
Lynparza (olaparib)	Merck	Commercial	Active
Oncology Portfolio	Pfizer	Phase 1-3	Multiple Active Programs
PD-1 Inhibitor	Akeso	Phase 2/3	Active
Mitoxantrone Liposome	CSPC Pharmaceutical Group Limited	Phase 3	Active
Biosimilar Bevacizumab	Cipla	Commercial	Active
Tazverik (tazemetostat)	Eisai	Commercial	Discontinuation announced
Oncology Generics	Aurobindo Pharma	Commercial	Active
Opdivo (nivolumab)	Ono Pharmaceutical	Approved	Commercial
Oncology APIs (e.g., Sorafenib, Lenalidomide)	Laurus Labs	Commercial/Filed	Active
Tumor Marker Portfolio (PSA, CA125, etc.)	H.U. Group Holdings	Commercial	Active
Logic-gated Switch-DARPins	Molecular Partners	Preclinical	Platform